Drug
Solriamfetol
Solriamfetol: highest development phase Post-Market, developed by Axsome Therapeutics, Jazz Pharmaceuticals. 13 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Axsome Therapeutics, Jazz Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Solriamfetol NCT04602936 | Post-Market | Binge Eating Disorder |
| Solriamfetol NCT04789174 | Post-Market | Excessive Daytime Sleepiness |
| Solriamfetol 75 MG NCT05838430 | Post-Market | Insomnia |
| Solriamfetol Oral Tablet NCT04788953 | Post-Market | Excessive Sleepiness |
| Solriamfetol 300 mg NCT06360419 | Phase 3 | Major Depressive Disorder |
| Solriamfetol NCT06878976 | Phase 3 | Binge-Eating Disorder |
| Solriamfetol 150 MG NCT07484217 | Phase 3 | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms |
| Solriamfetol NCT07773883 | Phase 3 | ADHD |
| Solriamfetol 150 mg NCT05972044 | Phase 3 | ADHD |
| Solriamfetol 150 mg NCT06413433 | Phase 3 | Binge-Eating Disorder |
| Solriamfetol 150 mg NCT06568367 | Phase 3 | Excessive Sleepiness |
| Solriamfetol NCT06170970 | Phase 2 | Multiple Sclerosis |
| Solriamfetol 150 mg Oral Tablet NCT05008341 | Phase 1 | Narcolepsy |
Latest
No recent events.
Follow Solriamfetol on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.